Lilly's revenue in the fourth quarter increased by 28% year-on-year to $9.35 billion, from Wall Street to Lujiazui
123458026
发表于 2024-2-7 11:26:22
1264
0
0
In the fourth quarter, Lilly's revenue was $9.35 billion, exceeding market expectations of $8.96 billion, with a year-on-year increase of 28%. Lilly's GLP-1 drug Zepbound is expected to dominate the weight loss market in 2024. However, Lilly faced limited production capacity in 2023 and took measures to increase supply in 2024.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Watch 7000 points on the S&P 500! Optimistic sentiment spreads on Wall Street, with two major banks singing more
- Is the layout of the Chinese stock market only for this moment? Wall Street's mysterious option buying has made a huge profit of $130 million
- Has the release of heavyweight data in the United States stabilized interest rate cuts? What do you think of Wall Street?
- Wall Street is guessing that the Federal Reserve won't be able to lower interest rates many times next year? There are still traders who don't buy it!
- Worries may become a reality! Wall Street frenzy hit hard, can the US stock market continue its strong performance next year
- Will there only be two interest rate cuts next year? Wall Street: The Federal Reserve may change its mind, and the current sell-off is a good opportunity to buy at the bottom!
- Major changes in the Federal Reserve! The prospect of interest rate cuts changes, leading to heated discussions on Wall Street
- Will the Federal Reserve return to the path of raising interest rates next year? Top Wall Street Economist: 40% Probability
- Global highlights next week: Wall Street cautious over Chinese New Year, key to Trump's long short relationship with Federal Reserve
- The seven giants of the US stock market all rose this year, and Tesla experienced a major reversal in the fourth quarter
